Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome

PHASE2TerminatedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions
Mucopolysaccharidosis IVAMorquio A SyndromeMPS IVA
Interventions
DRUG

BMN 110

Weekly IV infusions of BMN 110 at 2.0 mg/kg/week over a period of approximately 4 hours per infusion for up to 192 weeks.

DRUG

BMN 110

Weekly IV infusions of BMN 110 at 4.0 mg/kg/week over a period of approximately 4 hours per infusion for 27 weeks, and will eventually transition to 2.0 mg/kg/week for up to an additional 166 weeks.

Trial Locations (11)

Unknown

Oakland

Chicago

New York

Houston

Calgary

Toronto

Montreal

Sherbrook

Hamburg

Belfast

Manchester

Sponsors
All Listed Sponsors
lead

BioMarin Pharmaceutical

INDUSTRY